| Literature DB >> 29888284 |
Jin Sug Kim1, Gi-Ja Lee2, Tae Won Lee1, Chun Gyoo Ihm1, Yu Ho Lee1, Yang Gyun Kim1, Ju-Young Moon1, Sang Ho Lee1, Ji-Hye Kim2, Sung-Wook Kang2, Su-Jin Chae2, Hun-Kuk Park2, Kyung Hwan Jeong1.
Abstract
OBJECTIVE: Angiotensin II (Ang II) plays a profibrotic role in the kidneys. Although many pathways of Ang II have been discovered, the morphological and mechanical aspects have not been well investigated. We observed the changes in tubular epithelial cells (TECs) after Ang II treatment with or without Ang II receptor blockers (ARBs) using atomic force microscopy (AFM).Entities:
Mesh:
Substances:
Year: 2018 PMID: 29888284 PMCID: PMC5985133 DOI: 10.1155/2018/9208795
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Representative AFM topography (upper panels) and deflection images (lower panels) of fixed TECs. (a) No treatment; (b) Ang II injection; (c) Ang II + Telmisartan; (d) Ang II + PD123319; (e) Ang II + Blebbistatin. AFM: atomic force microscopy; TECs: tubular epithelial cells; Ang II: angiotensin II.
Figure 2Representative approach half of the force-distance curve in TECs. (a) No treatment; (b) Ang II injection; (c) telmisartan injection; (d) Ang II + Telmisartan; (e) Ang II + PD123319; (f) Ang II + Blebbistatin. Keff for calculated cellular spring constant (Kcell) is obtained from the slope of the linear region of the each FD curve for a cell. TECs: tubular epithelial cells; Ang II: angiotensin II.
Calculated spring constant of live TECs (n = 30) before and 20 min after Ang II stimulation with or without telmisartan, PD123319, and blebbistatin.
|
| Statistical significance | ||
|---|---|---|---|
| vs. No treatment | vs. Ang II | ||
| No treatment | 0.0093 ± 0.0025 |
| |
| Ang II injection | 0.0182 ± 0.0105 |
| |
| Telmisartan injection | 0.0104 ± 0.0021 |
| |
| Ang II injection + Telmisartan | 0.0096 ± 0.0030 |
| |
| Ang II injection + PD12319 | 0.0220 ± 0.0086 |
| |
| Ang II injection + Blebbistatin | 0.0118 ± 0.0023 |
|
|
TECs, tubular epithelial cells; Ang II, angiotensin II.
Figure 3Immunofluorescence staining for pMLC (upper panels), F-actin (mid panels), and E-cadherin (lower panels) of TECs. (a) No treatment; (b) Ang II injection; (c) Ang II + Telmisartan; (d) Ang II + PD123319; (e) Ang II + Blebbistatin. pMLC: phospho-myosin light chain; TECs: tubular epithelial cells; Ang II: angiotensin II.